Sugi Predict

Sugi Predict / Targets / LOX

LOX

Protein-lysine 6-oxidase · P28300 · LOX on Sugi Atlas →

15,939 patent compounds predicted against LOX, 8,778 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1838092 SCHEMBL1838092 0.58 17/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL463199) 0.96 14/20
SCHEMBL447701 SCHEMBL447701 0.54 14/20
SCHEMBL1853154 SCHEMBL1853154 0.47 13/20
SCHEMBL449200 SCHEMBL449200 1.00 12/20
SCHEMBL787866 SCHEMBL787866 0.56 9/20
SCHEMBL445278 SCHEMBL445278 0.50 8/20
SCHEMBL429686 SCHEMBL429686 0.54 7/20
SCHEMBL944345 SCHEMBL944345 0.53 7/20
SCHEMBL922635 SCHEMBL922635 0.42 7/20
SCHEMBL56319 SCHEMBL56319 0.57 6/20
SCHEMBL1680417 SCHEMBL1680417 0.53 6/20
SCHEMBL445290 SCHEMBL445290 0.70 5/20
SCHEMBL352525 SCHEMBL352525 0.61 5/20
SCHEMBL441300 SCHEMBL441300 0.60 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1413435) 0.58 5/20
SCHEMBL1654460 SCHEMBL1654460 0.55 5/20
SCHEMBL130180 SCHEMBL130180 0.67 4/20
SCHEMBL440214 SCHEMBL440214 0.57 4/20
SCHEMBL429671 SCHEMBL429671 0.51 4/20

Clinical trials — most relevant to LOX by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee PHASE4RECRUITING
Predicting Response to Standardized Pediatric Colitis Therapy PHASE4COMPLETED
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
Anti Inflammatory and Analgesic Effect of Ginger Powder in Dental Pain Model PHASE2UNKNOWN
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma PHASE1/PHASE2WITHDRAWN
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers PHASE1/PHASE2COMPLETED
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) PHASE2COMPLETED
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation PHASE2COMPLETED
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide PHASE1COMPLETED
NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM PHASE1WITHDRAWN
Endometriosis and Microvascular Dysfunction: Role of Inflammation EARLY_PHASE1RECRUITING
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Cardiovascular Disease Risk in Women With Endometriosis EARLY_PHASE1RECRUITING
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma nanCOMPLETED
Oxidized LDL With Oxygen Therapy in Acute Coronary Syndrome. nanUNKNOWN
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock nanCOMPLETED
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme nanNOT_YET_RECRUITING
Glycoxidation, Arterial Biomechanics, and Target Organ Damage nanRECRUITING
Fatty Acid Regulation of Platelet Function in Diabetes nanCOMPLETED
Pelvic Organs Prolapse Treatment Using Neodymium Laser nanACTIVE_NOT_RECRUITING
Lysine Oxidation in Response to Arginine Supplementation nanCOMPLETED
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
Oxidative Stress and Fatty Acids in Hepatitis C nanCOMPLETED
Oxidative Lipidomic Biomarkers During Mechanical Ventilation in Critically Ill Patients (OXY-BAL). nanRECRUITING
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
Personalizing Preterm Neonatal Transfusions With Fetal Hemoglobin-Enriched Cord Blood nanNOT_YET_RECRUITING
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B nanCOMPLETED
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults nanCOMPLETED
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer nanCOMPLETED
Heart & Health Study nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LOX binder may also engage these)

ProteinNameSimilarity
P28301 — 1.000 P28301 →
P33072 — 1.000 P33072 →
P16636 — 1.000 P16636 →
Q05063 — 1.000 Q05063 →
Q95L39 — 0.999 Q95L39 →
LOXL1 Lysyl oxidase homolog 1 0.997 landscape →
P97873 — 0.995 P97873 →
Q701R2 — 0.979 Q701R2 →
A6QLD2 — 0.977 A6QLD2 →
Q8BHP7 — 0.975 Q8BHP7 →
Q98ST5 — 0.974 Q98ST5 →
O14511 — 0.974 O14511 →
Q76KP1 — 0.973 Q76KP1 →
Q90322 — 0.973 Q90322 →
A2A699 — 0.973 A2A699 →
C0HKU1 — 0.972 C0HKU1 →
Q8R2G6 — 0.972 Q8R2G6 →
Q6ZSJ9 — 0.972 Q6ZSJ9 →
Q86X29 — 0.972 Q86X29 →
Q9VZX1 — 0.972 Q9VZX1 →
P04488 — 0.972 P04488 →
Q16650 — 0.972 Q16650 →
Q3U2S4 — 0.972 Q3U2S4 →
A2RUV9 — 0.972 A2RUV9 →
O60292 — 0.972 O60292 →
Q5QQ37 — 0.971 Q5QQ37 →
Q5NRQ0 — 0.971 Q5NRQ0 →
O18738 — 0.971 O18738 →
Q2THW0 — 0.971 Q2THW0 →
A4VCL2 — 0.971 A4VCL2 →